#### <sup>1</sup>**Deciphering autoantibody landscape of systemic sclerosis through systems-based**

#### <sup>2</sup>**approach: insights from a B-cell depletion clinical trial**

- $\overline{3}$
- 4 Kazuki M Matsuda, MD, PhD,<sup>1</sup> Satoshi Ebata, MD, PhD,<sup>1</sup> Kazuhiro Iwadoh, MD,
- 5 PhD,<sup>1</sup> Hirohito Kotani, MD, PhD,<sup>1</sup> Teruyoshi Hisamoto, MD, PhD,<sup>1</sup> Ai Kuzumi, MD,
- 6 PhD,<sup>1</sup> Takemichi Fukasawa MD, PhD,<sup>1,2</sup> Asako Yoshizaki-Ogawa, MD, PhD,<sup>1</sup> Shinichi
- 7 Sato, MD, PhD,  $1$  Ayumi Yoshizaki, MD, PhD $^{1,2\#}$
- 
- 9 1. Department of Dermatology, The University of Tokyo Graduate School of Medicine,
- 10 Tokyo, Japan
- 11 2. Department of Clinical Cannabinoid Research, The University of Tokyo Graduate
- 12 School of Medicine, Tokyo, Japan

#### <sup>14</sup>**# Corresponding author**

<sup>15</sup>Ayumi Yoshizaki, MD, PhD

- 16 Department of Dermatology and Department of Clinical Cannabinoid Research, The
- 17 University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo,
- 18 Japan, 1138655
- 19 Phone: +81-3-3815-5411
- 20 ORCID: 0000-0002-8194-9140
- 21 E-mail: ayuyoshi@me.com
- 22

## **Abstract**



- 41 autoantibody profiling could enhance diagnostic and therapeutic strategies, and
- 42 moreover, better understanding of the pathophysiology of SSc.

43

# **Introduction**



60 of the study period. The open-label extension of this trial also revealed the long-term

61 efficacy and safety of RTX on  $SSc$ ,<sup>14</sup> as well as the association between decrease in 62 serum immunoglobulins and greater clinical response to RTX.<sup>15</sup>



75 Herein, we employed our original technique for proteome-wide autoantibody 76 screening (PWAS) using wet protein arrays (WPAs) that cover approximately 90% of 77 the human transcriptome.<sup>18,19</sup> This technique has previously been used to develop 78 multiplex measurements for disease-related autoantibodies, $20,21$  identify clinically



## **Results**

*Subjects* 



- 103 we categorized the RTX treatment group into two subgroups based on their response to
- 104 treatment (**Figure 1D**): high responders (HRs;  $n = 11$ ) and low responders (LRs;  $n = 13$ ).



## <sup>114</sup>*Machine learning*

115 To determine which autoantibodies were driving the association between the 116 SAL and disease status, we firstly utilized nine machine learning frameworks. Notably, <sup>117</sup>Lasso regression, Ridge regression, SVM with normalization, XGBoost, and LightGBM 118 achieved an area under the receiver-operator characteristics curve (ROC-AUC) 119 exceeding 0.96, demonstrating an almost perfect ability to distinguish between SSc 120 patients and HCs (Table 2). We identified the top 10 features in these six models <sup>121</sup>(**Extended Figure 2A**), examined their inclusion relationships (**Extended Figure 2B**), 122 and explored the prevalence of highlighted autoantibodies across a broader range of



<sup>130</sup>*Investigating clinically relevant autoantibodies* 

131 We next sought to identify autoantibodies significantly associated with the 132 clinical features of SSc using the trial data that included longitudinal changes. Initially, 133 we selected autoantibodies that were significantly elevated in SSc patients compared to <sup>134</sup>HCs at baseline (**Figure 2A**). Next, we chose autoantibodies that were significantly 135 higher in HRs compared to LRs (**Figure 2B**). Lastly, we focused on autoantibodies 136 whose serum concentrations significantly decreased from week 0 to week 24 in HRs <sup>137</sup>(**Figure 2C**). As a result, 58 autoantibodies were identified as candidates for clinically 138 relevant autoantibodies in SSc (**Figure 2D**). Principal component analysis (PCA) 139 indicated that these 58 autoantibodies appear to distinguish HRs at week 0 within the 140 dataset (**Figure 2E**). The sum of the serum levels of these autoantibodies displayed a



146

## <sup>147</sup>*Profiling candidate autoantibodies*

<sup>148</sup>To explore the molecular features of the human proteins targeted by the 149 identified candidate autoantibodies, we conducted gene ontology enrichment analyses 150 utilizing Metascape.<sup>25</sup> Notably, whereas established SSc-related autoantibodies 151 primarily target intracellular antigens, our findings emphasized membrane proteins 152 associated with processes such as "import across plasma membrane" and "peptide G 153 protein-coupled receptors (GPCRs)" (Figure 3A). There were four autoantibodies 154 linked to each of the processes "import across plasma membrane" and "peptide GPCRs" <sup>155</sup>(**Figure 3B**). Autoantibodies associated with plasma membrane import included those 156 targeting presenilin 1 (PSEN1), solute carrier family 22 member 2 (SLC22A2), transient 157 receptor potential cation channel subfamily V member 5 (TRPV5), and solute carrier 158 family 46 member 1 (SLC46A1; **Figure 3C**). The group related to peptide GPCRs



# <sup>174</sup>*Weighted correlation network analysis*

175 We utilized weighted correlated network analysis  $(WGCNA)^{28}$  to delve deeper 176 into the correlations between autoantibodies in SSc. Our study included 135 specimens



194 Questionnaire (HAQ) scores and lower 36-Item Short Form Health Survey (SF-36)

193 lower patient-reported quality of life, evidenced by higher Health Assessment

- 195 scores. The "darkmagenta" module was associated with ARA positivity and higher
- 196 forced vital capacity of the lungs, indicating a lower degree of ILD. The "tan" module
- 197 was correlated with the ACA profile but did not show any significant associations with
- 198 other clinical traits
- 

## **Discussion**





234 autoantibodies and the pathogenesis of SSc. CCR8 is primarily expressed on Tregs

233 studies have indicated the relationship between GPCRs targeted by the candidate





261 Meanwhile, it is important to note that the serum levels of the candidate 262 autoantibodies we identified were relatively modest compared to conventional 263 SSc-specific autoantibodies like ATA (**Extended Figure 1B**). Moreover, the presence 264 of these candidate autoantibodies did not appear to be specific to SSc, as indicated by 265 data from UT-ABCD (**Extended Figure 3A and 3B**). These suggest that the 266 pathogenesis of SSc may not be attributed to a single unique autoantibody that shows 267 strong cross-reactivity with conventional SSc-specific autoantibodies, but rather to a 268 collaboration of multiple autoantibodies. This hypothesis aligns with several 269 observations that suggest that SSc is a multifactorial disease, involving a combination 270 of various autoantibodies and other factors rather than a single causative factor. First,

medRxiv preprint doi: [https://doi.org/10.1101/2024.07.30.24311212;](https://doi.org/10.1101/2024.07.30.24311212) this version posted July 31, 2024. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has granted me

271 genome-wide association studies have not identified a single gene mutation strongly 272 linked to  $SSc<sup>43</sup>$  Second, the disease concordance in twins is modest and similar 273 between monozygotic and dizygotic twins, further supporting the notion that SSc is not 274 caused only by genetic factors.<sup>44</sup> Finally, and most importantly, the clinical 275 manifestations of SSc are highly heterogeneous.<sup>1</sup>

276 Alternatively, a cluster of several autoantibodies, with combinations that vary 277 among patients, might explain the heterogeneity of clinical manifestations in SSc.<sup>45</sup> 278 Co-localization of ATA and candidate autoantibodies within the same module identified 279 by WGCNA, as well as the distribution of ATA, ARA, and ACA among different <sup>280</sup>modules (**Figure 4**), support this hypothesis. Such clustering of autoantibodies might 281 result from cross reaction with a single specific exogenous antigen such as viruses,  $46,47$ 282 or intermolecular epitope spreading, a phenomenon we have recently demonstrated to 283 be involved in SSc progression using the same WPA system. Further research is needed 284 to unravel the relationships among these autoantibodies and their collective contribution 285 to SSc development. This research should include comparisons of structural similarity 286 and epitope mapping for the relevant antigens, and longitudinal serological monitoring 287 in each case. Understanding these interactions will be crucial for comprehensively

288 elucidating the mechanisms underlying the autoimmune aspect of SSc and potentially 289 identifying new therapeutic targets.

290 Our study has several notable strengths. Firstly, the data presented is derived 291 from a prospective, randomized, placebo-controlled clinical trial, which includes two 292 time points (before and after RTX therapy). This adherence to good clinical practice 293 ensures high data accuracy. Secondly, the use of the wheat-germ *in vitro* protein 294 synthesis system and the manipulation technique for WPAs enabled high-throughput 295 expression of a variety of human proteins, including membranous proteins, on a single 296 platform.<sup>18</sup> As a result, our autoantibody measurement could encompass a wider range 297 of antigens at an almost proteome-wide level, allowing for the application of 298 omics-based bioinformatics approaches to interpret the data.<sup>24</sup> Meanwhile, one major <sup>299</sup>limitation is the lack of functional assays both *in vitro* and *in vivo*. Further investigation 300 is needed to determine whether the candidate autoantibodies we identified act as 301 agonists or antagonists to their target proteins, and whether they influence the 302 pathophysiology of SSc. Moreover, the value of autoantibodies we identified for 303 predicting treatment response to RTX should be validated in external cohorts in 304 real-world clinical settings.

## <sup>306</sup>**References**







- 342 (DESIRES): open-label extension of a double-blind, investigators-initiated,
- <sup>343</sup>randomised, placebo-controlled trial. *Lancet Rheumatol.* **<sup>4</sup>**, e546–e555 (2022).
- 344 15. Kuzumi, A. *et al.* Long-term Outcomes After Rituximab Treatment for Patients
- 345 With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on
- 346 Serum Immunoglobulin Levels. *JAMA Dermatology* 159, 374–383 (2023).
- <sup>347</sup>16. Okano, Y. Antinuclear antibody in systemic sclerosis (scleroderma). *Rheum Dis*
- <sup>348</sup>*Clin North Am* **<sup>22</sup>**, 709–35 (1996).
- 349 17. Nihtyanova, S. I. & Denton, C. P. Autoantibodies as predictive tools in systemic

350 sclerosis. *Nat. Rev. Rheumatol.* **6**, 112–116 (2010).

- 351 18. Goshima, N. *et al.* Human protein factory for converting the transcriptome into
- <sup>352</sup>an in vitro-expressed proteome. *Nat. Methods* **<sup>5</sup>**, 1011–1017 (2008).
- 353 19. Fukuda, E. *et al.* Identification and characterization of the antigen recognized by
- 354 the germ cell mAb TRA98 using a human comprehensive wet protein array.
- <sup>355</sup>*Genes to Cells* **<sup>26</sup>**, 180–189 (2021).
- 356 20. Matsuda, K. M. *et al.* Autoantibody Landscape Revealed by Wet Protein
- 357 Array : Sum of Autoantibody Levels Re fl ects Disease Status. *Front. Immunol.*
- <sup>358</sup>**13**, 1–14 (2022).





- <sup>378</sup>single-cell transcriptomic atlas of humans. *Science (80-. ).* **<sup>376</sup>**, eabl4896 (2022).
- 379 28. Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation
- <sup>380</sup>network analysis. *BMC Bioinformatics* **<sup>9</sup>**, (2008).
- 381 29. Moritz, C. P. *et al.* Autoantigenomics: Holistic characterization of autoantigen
- 382 repertoires for a better understanding of autoimmune diseases. Autoimmun. Rev.
- <sup>383</sup>**19**, 102450 (2020).
- 384 30. Matsuda, K. M. *et al.* Development of a prediction model of treatment response
- 385 in patients with cutaneous arteritis: I: Insights from a cohort of 33 patients. *J.*
- <sup>386</sup>*Dermatol.* **<sup>48</sup>**, 1021–1026 (2021).
- 387 31. Cabral-Marques, O. *et al.* GPCR-specific autoantibody signatures are associated
- <sup>388</sup>with physiological and pathological immune homeostasis. *Nat. Commun.* **<sup>9</sup>**, 5224
- 389 (2018).
- <sup>390</sup>32. Cabral-marques, O. *et al.* Autoantibodies targeting GPCRs and RAS-related
- <sup>391</sup>molecules associate with COVID-19 severity. *Nat. Commun.* **<sup>13</sup>**, 1220 (2022).
- 392 33. Akbarzadeh, R., Müller, A., Humrich, J. Y. & Riemekasten, G. When natural
- 393 antibodies become pathogenic: autoantibodies targeted against G



- <sup>395</sup>*Immunol.* **<sup>14</sup>**, 1213804 (2023).
- <sup>396</sup>34. Barsheshet, Y. *et al.* CCR8+FOXp3+ Treg cells as master drivers of immune
- <sup>397</sup>regulation. *Proc. Natl. Acad. Sci.* **<sup>114</sup>**, 6086–6091 (2017).
- <sup>398</sup>35. Tiffany, H. L. *et al.* Identification of CCR8: a human monocyte and thymus
- 399 receptor for the CC chemokine I-309. *J. Exp. Med.* **186**, 165–170 (1997).
- 400 36. Mcdonald, B. *et al.* Intravascular Danger Signals Guide Neutrophils to Sites of
- <sup>401</sup>Sterile Inflammation. *Science (80-. ).* **<sup>330</sup>**, 362–367 (2011).
- 402 37. Zhang, Q. *et al.* Circulating mitochondrial DAMPs cause inflammatory responses
- <sup>403</sup>to injury. *Nature* **<sup>464</sup>**, 104–107 (2010).
- 404 38. Napolitano, F. *et al.* N-formyl peptide receptors induce radical oxygen
- 405 production in fibroblasts derived from systemic sclerosis by interacting with a
- 406 cleaved form of urokinase receptor. *Front. Immunol.* 9, (2018).
- 407 39. Getting, S. J. Targeting melanocortin receptors as potential novel therapeutics.
- <sup>408</sup>*Pharmacol. Ther.* **<sup>111</sup>**, 1–15 (2006).
- <sup>409</sup>40. Kokot, A. *et al.* <sup>α</sup>-melanocyte–stimulating hormone suppresses
- <sup>410</sup>bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse





# <sup>441</sup>**Acknowledgements**



## <sup>447</sup>**Author Contributions**



## <sup>456</sup>**Conflict-of-interest statement**



#### <sup>464</sup>**Materials and Methods**

<sup>465</sup>*Study Design* 

466 The study design for the DESIRES trial has been previously reported 467 (NCT04274257).<sup>13</sup> Briefly, the DESIRES trial was a randomized, double-blind, 468 placebo-controlled trial of 24 weeks. In total, 56 patients were randomized to receive 469 either intravenous rituximab (375 mg/m<sup>2</sup>) or matching placebo once per week for 4 470 weeks. Of these, 49 patients completed the double-blind phase. Serum samples were 471 collected and served for PWAS at the beginning and the end of the double-blind phase <sup>472</sup>(**Fig. 1A**). After excluding 4 cases due to their serum unsuitable for PWAS, data of 45 473 patients were included in our analysis. Age and sex matched HCs were selected from a 474 cohort of healthcare providers on annual checkups without any medical history (**Fig. Fig. 1B**), using "matchIt" R package.<sup>48</sup> This study was approved by the ethics committee of 476 the University of Tokyo Graduate School of Medicine and conducted in accordance 477 with the Declaration of Helsinki. Written informed consent was obtained from all 478 patients.

<sup>480</sup>*Assessments* 



# *Autoantibody measurement*

495 WPAs were arranged as previously described.<sup>20</sup> First, proteins were 496 synthesized *in vitro* utilizing a wheat germ cell-free system from 13,455 clones of the 497 HuPEX.<sup>18</sup> Second, synthesized proteins were plotted onto glass plates (Matsunami 498 Glass, Osaka, Japan) in an array format by the affinity between the GST-tag added to



$$
Autoantibody level [AU] = \frac{F_{autoantigen} - F_{negative \ control}}{F_{positive \ control} - F_{negative \ control}} \times 100
$$

510 AU arbitrary unit

511  $F_{\textit{autoantigen}}$ : fluorescent intensity of autoantigen spot

512  $F_{\text{negative control}}$  fluorescent intensity of negative control spot

513  $F_{positive\,control}$  fluorescent intensity of positive control spot

514

<sup>515</sup>*Machine learning* 



### *WGCNA analysis*

531 The weighted gene co-expression network was constructed using the 532 "WGCNA" R package.<sup>28</sup> We calculated each gene pair's Pearson correlation coefficient, 533 measured how similarly their expressions were expressed, and created a correlation



<sup>551</sup>*Data visualization* 



558

### **Figure legends**

**Figure 1. Overview of the study. (A)** The study design of the DESIRES trial. **(B)** The flow chart of sample acquisition in the present study. (C) The sum of autoantibody levels (SAL) in SSc at the baseline and HCs. (D) Absolute change of mRSS in SSc patients during the DESIREs trial. HR: high responder, LR: low responder. (E) SAL before and after the study period of the DESIRES trial by the treatment arm. (F) Serum levels of SSc-related autoantibodies before and after the study period of the DESIRES trial by the treatment arm. ATA: anti-topoisomerase I antibody, ACA: anti-centromere antibody, ARA: anti-RNA polymerase III antibody. \*: P < 0.05, \*\*\*\*: P < 0.0001, NS:  $P > 0.05$ . P values were calculated by Mann-Whitney's U test.

#### **Figure 2. Selection of autoantibodies of clinical relevance.**

**(A)** Volcano plot that shows autoantibodies differentially elevated in SSc before treatment compared to HCs. The vertical dash line indicates  $P = 0.05$ . **(B)** Volcano plot that shows autoantibodies differentially increased in HRs than in LRs. **(C)** Volcano plot that shows autoantibodies significantly reduced in HRs during RTX therapy. **(D)** Heat map that shows the serum levels of 58 candidate autoantibodies of clinical relevance. **(E)** Principal component analysis of 58 candidate autoantibodies of clinical relevance. In the scatter plot, individual subjects as points. The loading diagram illustrates the contributions to PC1 and PC2. **(F)** SAL focused on 58 candidate autoantibodies of clinical relevance. \*\*\*: P < 0.001, \*\*\*\*: P < 0.0001, NS: P > 0.05. P values were calculated by Mann-Whitney's U test. **(G)** The receiver-operator characteristics (ROC) curve demonstrating the discrimination between SSc and HCs by all the measured autoantibodies (green) and by 58 candidate autoantibodies of clinical relevance (yellow). **(H)** The ROC curve demonstrating the discrimination between HRs and LRs by all the measured autoantibodies (green) and by 58 candidate autoantibodies of clinical relevance (yellow).

#### **Figure 3. Proteins targeted by the candidate autoantibodies of clinical relevance.**

**(A)** Gene ontology analysis encompassing the genes coding proteins targeted the candidate autoantibodies. **(B)** The circos plot represents the inclusion relationship between each gene ontology and the candidate autoantibodies. **(C)** Serum levels of candidate autoantibodies associated with "import across plasma membrane." **(D)** The heatmap illustrates correlation between the candidate autoantibodies associated with "import across plasma membrane" and clinical traits of SSc. **(E)** Serum levels of autoantibodies associated with "peptide GPCRs." **(F)** The heatmap illustrates correlation between the candidate autoantibodies associated with "peptide GPCRs" and clinical traits of SSc. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ . P values were calculated by Spearman's correlation test.

**Figure 4. WGCNA analysis. (A)** Network heatmap plot. Branches in the hierarchical clustering dendrograms correspond to modules. Color-coded module membership is displayed in the color bars below and to the right of the dendrograms. In the heatmap, high co-expression interconnectedness is indicated by progressively more saturated yellow and red colors. **(B)** Gene ontology analysis encompassing the genes coding proteins targeted by autoantibodies included in the "turquoise," "darkmagenta," and "tan" modules. **(C)** The heat map illustrates correlation between each module identified by WGCNA analysis and clinical traits of SSc. **(D)** The heatmap shows the correlation between each module and clinical trait. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ , \*\*\*\*: P < 0.0001. P values were calculated by Spearman's correlation test.

#### **Extended Figure 1. Additional results of PWAS. (A) The** sum of autoantibody levels

(SAL) by age groups. **(B)** Serum levels of SSc-related autoantibodies before and after

the DESIRES trial by the treatment arm and responsiveness.

#### **Extended Figure 2. Autoantibodies highlighted in each machine learning model.**

**(A)** Autoantibodies that were mostly highlighted according to feature importance by Lasso regression, Ridge regression, SVM with normalization, Random Forest, XGBoost, and LightGBM. **(B) The** inclusion relationship of autoantibodies highlighted by the six machine learning frameworks illustrated by an UpSet plot. **(C)** The box plots describe the serum levels of autoantibodies highlighted by more than two frameworks in COVID-19, atopic dermatitis (AD), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and healthy controls (HCs). The data derives from the UT-ABCD.

#### **Extended Figure 3. Distribution of the candidate autoantibodies among various**

**disorders.** The box plots describe the serum levels of the candidate autoantibodies associated with "import across plasma membrane" **(A)** and "peptide GPCRs" **(B)** in COVID-19, atopic dermatitis (AD), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and healthy controls (HCs). The data derives from the UT-ABCD.

#### **Extended Figure 4. Expression of highlighted autoantigens in human tissues and**

**single cells.** Expression of autoantigens associated with "import across plasma membrane" **(A)** or with "peptide GPCRs" **(B)** in multiple human tissues, as measured by bulk RNA-sequencing from the Human Protein Atlas. Expression of CCR8 **(C)** or FPR1 **(D)** in immune cells from multiple human tissues, as measured by single-cell RNA-sequencing from the Tabula Sapiens project.

![](_page_45_Figure_0.jpeg)

![](_page_46_Figure_0.jpeg)

Figure 2

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit

# **Gene Ontology Analysis**

![](_page_47_Figure_2.jpeg)

GO:0098739: import across plasma membrane WP24: Peptide GPCRs GO:0006281: DNA repair GO:1904063: negative regulation of cation transmembrane transport GO:0043467: regulation of generation of precursor metabolites and energy GO:0043484: regulation of RNA splicing R-HSA-112316: Neuronal System

B

A

![](_page_47_Picture_216.jpeg)

![](_page_47_Figure_6.jpeg)

![](_page_47_Figure_7.jpeg)

![](_page_47_Figure_8.jpeg)

![](_page_47_Figure_9.jpeg)

Matsuda KM et al. Figure 3

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit

![](_page_48_Figure_1.jpeg)

![](_page_48_Picture_58.jpeg)

![](_page_48_Figure_3.jpeg)